Investigational treatments for cytomegalovirus infection in phase I and II study. (PubMed, Expert Opin Investig Drugs) - Oct 21, 2025 - "Despite recent advances in CMV chemoprevention and treatment in transplant recipients, there remains a need for a broader, more diversified approach to mitigating the impact of CMV infection in both transplant and non-immunocompromised persons. Intravenous brincidofovir would provide an important alternative option to current antivirals in the right clinical setting. Several promising vaccine candidates are in various stages of clinical development. A safe and effective vaccine may also expand preventative strategies beyond transplant recipients and into healthy persons, specifically for the prevention of maternal-to-fetal transmission. The therapeutic possibilities of VST and TCR therapy represent important potential adjuncts to antivirals."
Journal • P1 data • Review • Cytomegalovirus Infection • Infectious Disease • Transplantation
|
|
Anat Stern; Genovefa A Papanicolaou; Morgan Hakki
|